Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic

• Published in: The Lancet (British edition) Vol. 354; no. 9190; p. 1615
• Main Authors: Peruzzi, Licia, Gianoglio, Bruno, Porcellini, Maria Gabriella, Coppo, Rosanna
• Format: Journal Article
• Language: English
• Published: London Elsevier Ltd 06-11-1999; Lancet; Elsevier Limited
• Subjects: Adult; Babies; Biological and medical sciences; Births; Cyclooxygenase Inhibitors - adverse effects; Drug therapy; Drug toxicity and drugs side effects treatment; Female; Humans; Infant, Newborn; Ingestion; Kidney Failure, Chronic - chemically induced; Kidneys; Medical sciences; Obstetric Labor, Premature - prevention & control; Pharmacology. Drug treatments; Pregnancy; Prenatal development; Prenatal Exposure Delayed Effects; Sulfonamides - adverse effects; Toxicity: urogenital system; Kidney disease; Pediatrics; Neonatal; Urinary system disease; Oral administration; Terminal stage; Mother child relation; Non steroidal antiinflammatory agent; Case study; Chemotherapy; Analgesic; Association; Risk factor; Renal failure; Antipyretic; Nimesulide
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(99)03105-0

Cyclo-oxygenase-type-2 (COX-2) enzyme is fundamental for nephrogenesis, upregulated on fetal membranes and myometrium at parturition. Fetal COX-2 inhibition, due to maternal nimesulide assumption, can be responsible for neonatal chronic renal failure.